In the UK, getting Mounjaro® or Wegovy® through the NHS is possible on paper and hard in practice: primary-care access is rationed by cohorts (currently BMI 35 or more plus 4 qualifying conditions out of 5), Wegovy is limited to specialist services with multi-month waits, and more than 1.5 million Britons simply pay privately. Here is how the system actually works in 2026, with sources, and how it compares with France’s new reimbursement scheme.
⚕️ This article summarizes public UK and French information (NICE, NHS England, peer-reviewed studies, official texts) for information only. It is not medical advice, and access rules change: always check with your GP or pharmacist.
The 30-second version
- Mounjaro via your GP: rolled out in cohorts since June 2025. Cohort 2 (open since 23 June 2026) requires a BMI of 35 to 39.9 plus 4 of 5 qualifying conditions; cohort 1 required BMI 40+ with the same 4 of 5
- Meeting the criteria does not guarantee access: central funding for year one covered roughly 10% of the 220,000-patient target, and since April 2026 prescribing sits in a voluntary part of the GP contract
- Wegovy on the NHS: specialist weight-management services only, for a maximum of 2 years; just 838 NHS prescriptions were issued in its first 8 months
- Private route: over 1.5 million people in the UK pay out of pocket, roughly £150 to £315+ per month for Mounjaro and £100 to £240 for Wegovy
- France, by contrast, reimburses both drugs at 65% from BMI 35 with a single listed comorbidity (or BMI 40 alone), after a 6-month nutritional pathway
How the NHS decides: NICE first, then a very slow rollout
England’s process has two layers. First, NICE (the National Institute for Health and Care Excellence) assesses a drug. For tirzepatide (Mounjaro), its December 2024 guidance recommends treatment for adults with a BMI of 35 or more and at least one weight-related comorbidity, which corresponds to about 3.4 million people in England. Thresholds are lowered by 2.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.
Then comes the unusual part: because of the budget impact, NHS England obtained an implementation period of up to 12 years, with only about 220,000 patients targeted over the first three. Access is therefore opened by narrow cohorts:
| Cohort | Opens | Criteria |
|---|---|---|
| 1 | 23 June 2025 | BMI ≥ 40 (≥ 37.5 adjusted) + 4 of 5 conditions |
| 2 | 23 June 2026 (current) | BMI 35–39.9 (32.5–37.4 adjusted) + 4 of 5 conditions |
| 3 | 1 April 2027 | BMI ≥ 40 + 3 of 5 conditions |
The 5 qualifying conditions are: type 2 diabetes, treated hypertension, dyslipidemia, obstructive sleep apnea, and established cardiovascular disease. The BMI must be measured at referral: historical values are not accepted.
Eligible on paper is not the same as treated
Three sourced reality checks:
- Funding: an investigation published by the BMJ found that two months after launch, only 18 of England’s 42 integrated care boards had actually started prescribing, and that year-one funding covered roughly 10% of the three-year target of 220,000 patients.
- Local restrictions: several boards added their own criteria on top of the national ones, and allocations can be tiny. One board’s service specification allowed a maximum of 425 patients for 2025/26, against about 230,000 people on its obesity registers.
- Since April 2026: central funding for these local services ended, and prescribing moved into the GP contract as an optional, incentivized activity. One NHS board states it plainly: meeting the eligibility criteria does not guarantee access to treatment, and pauses in prescribing are possible.
Patients also need to accept “wraparound care” (dietary and behavioral support), with treatment stopping if they disengage, and dose-titration appointments every 4 weeks.
Wegovy on the NHS: a narrow, slow door
Wegovy has been NICE-recommended since March 2023, but only within specialist weight-management services (tier 3 and 4), and for a maximum of 2 years. A study in Clinical Obesity based on freedom-of-information requests found the consequences: 838 NHS prescriptions in its first 8 months across all of England, about 50,000 people sitting on tier-3 waiting lists, and an average wait of 7.9 months, ranging from 2 to 36 months depending on the area. Patient groups have reported people being told to expect around two years before treatment.
The private route: where the volume actually is
Faced with those waits, most UK patients pay. Analysis by IQVIA estimated that over 1.5 million UK residents were accessing GLP-1 drugs privately as of March 2025, and a UCL survey published in early 2026 found that about 1.6 million adults in Great Britain had used a weight-loss medicine in the previous year. Typical private prices in August 2026: Mounjaro from about £150 (2.5 mg) to £315 or more (15 mg) per month, Wegovy from about £100 to £240. Prices moved sharply in September 2025, when the manufacturer raised Mounjaro’s UK list price before agreeing to a lower supplier price; NHS prices were not affected.
Two 2026 additions on the private market: a higher 7.2 mg Wegovy dose (approved in January 2026) and the first weight-loss GLP-1 tablet, Wegovy in pill form (approved in June 2026, licensed from BMI 30, or 27 with a comorbidity), sold from about £88 to £209 per month. Neither is currently available through the NHS.
UK vs France: two philosophies
For readers who live between the two systems, the contrast is striking:
| England (NHS) | France (since 15 June 2026) | |
|---|---|---|
| Entry threshold in practice | BMI 35+ with 4 of 5 conditions (cohort 2) | BMI 40 alone, or 35 with 1 of 14 listed comorbidities |
| Prior requirement | Wraparound care alongside treatment | 6-month nutritional pathway with < 5% loss, before treatment |
| Who prescribes first | GP practices that opted in (Mounjaro) or specialist services (Wegovy) | Authorized specialists (obesity centers, teaching hospitals) |
| Duration limits | None for Mounjaro; 2 years for NHS Wegovy | None set by the orders; review around 2 years per HAS |
| Cost when covered | Standard NHS prescription charge | 65% reimbursed; usually ≈ €1 per box with top-up insurance |
France’s rules are broader on paper, with their own bottleneck: the first prescription requires a specialist, with waits that patients report at 3 to 8 months. If you live in France, our eligibility checker and coverage guide walk you through it.
While you wait, whichever country you are in
Whether you are queueing for a tier-3 service, waiting for cohort 3 (April 2027), or paying privately, the constant is the paperwork of your own body: when you inject, what dose, what your weight does, how you feel. Bring that record to every appointment; it is what clinicians act on.
📱 NHS or private, the tracking is the same. The Doza app logs your weekly shots, weight and effects in a few seconds, and your measurements and doses never leave your iPhone. 14-day free trial on the annual plan. Discover Doza →
FAQ — GLP-1 coverage in the UK
Am I eligible for NHS Mounjaro right now?
In 2026, primary-care access is open to cohorts 1 and 2: BMI 35 or more (adjusted for some ethnic backgrounds) plus 4 of the 5 qualifying conditions. Even then, access depends on whether your GP practice participates.
Why will my GP not prescribe it?
Since April 2026, prescribing sits in an optional part of the GP contract, and many practices have not opted in or have no capacity. That is a funding design choice, not your GP being difficult.
How long are NHS waits for Wegovy?
Specialist-service waits averaged 7.9 months in the published data, with extremes up to 36 months, and some patients report being told about two years.
Is the private route legitimate?
Buying through a registered UK pharmacy with a proper prescription is legal and common: over 1.5 million people do it. Avoid any seller that skips the prescription.
What changes on 1 April 2027?
Cohort 3 is due to open: BMI 40 or more with 3 of the 5 conditions, instead of 4. Rollout details will depend, again, on local funding.
Is it easier in France?
The entry criteria are broader (BMI 35 with one comorbidity), but the first prescription requires an authorized specialist and the pathway has its own 6-month prerequisite. See our France eligibility checker.
Sources: NICE TA1026, 23 December 2024 and NHS England interim commissioning guidance (cohorts, funding variation) · NHS Cheshire & Merseyside (cohort dates, “eligibility does not guarantee access”, updated 2 April 2026) · NICE TA875, 8 March 2023 (Wegovy, specialist services, 2 years) · BMJ press release, 4 September 2025 (18 of 42 boards, ~10% of the 220,000 target) · de Bray et al., Clinical Obesity 2026 (838 prescriptions, 7.9-month waits) · IQVIA analysis via BJGP 2025 (> 1.5 million private users) · UCL / BMC Medicine, January 2026 (1.6 million users in a year) · Which?, 24 August 2026 (private prices) · GOV.UK / MHRA (Wegovy 7.2 mg, January 2026; Wegovy pill, June 2026) · France: orders of 10 June 2026. Last updated: 29 August 2026. Published by Doza (INFINI CONSULTING), a French GLP-1 tracking app.